olverembatinib

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

A Study of Olverembatinib in SDH-deficient GIST.

Named Patient Program for Olverembatinib (HQP1351)

A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

A Study of Olverembatinib in the Treatment of Ph+ ALL

Olverembatinib for FGFR1-rearranged Neoplasms